-Sir William Osler 1 I magine the tragedy caused by the sudden and unexpected death of a loved one or family member. Without a premorbid course of worsening health or a previous diagnosis of life-threatening disease, the natural question that plagues surviving family members after sudden cardiac death (SCD) is, "why did this happen?" Autopsies in people age 1 to 40 years with sudden unexpected death identify a clear structural cardiovascular cause in approximately two-thirds of cases, with one-third designated "autopsy-negative sudden unexplained death syndrome" or SUDS. 2 Whole exome molecular autopsy has the ability to clarify genetic contributions to SUDS, when properly used. 3 And furthermore, postmortem DNA sequencing can also be very valuable for family members when people die with a clear genetic disorder, such as Marfan syndrome, hypertrophic cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy, which is now more commonly called arrhythmogenic cardiomyopathy (ACM), a term used to encompass cardiomyopathy affecting the right, left, or both ventricles with prominent arrhythmia.
Two articles in the current issue of Circulation support this approach, taking on the important challenge of clarifying the genetic contributions to sudden unexplained death. 4, 5 Finland is somewhat geographically isolated in Northern Europe. 6 Gene variation in the Finnish population has been remarkably well studied, in part because of its reduced ethnic diversity and its high level of genetic homogeneity. Junttila and colleagues 4 focused on autopsies from 4031 consecutive SCD victims in Northern Finland. Coronary heart disease was the most common cause of death (76%), whereas 971 people had nonischemic causes of SCD. In this subset, 145 (15% of nonischemic SCD, or 3.6% of the total SCD population) had primary myocardial fibrosis on autopsy, without evidence of another form of cardiomyopathy such as hypertrophic cardiomyopathy, ACM, or myocarditis. They hypothesized that primary myocardial fibrosis was attributable to early manifestation of an underlying genetic disorder. Accordingly, they successfully extracted DNA from formalin-fixed paraffin-embedded tissue in 96 (66%) patients, and utilized nextgeneration sequencing of 174 genes in which mutations are known or suspected to cause familial forms of cardiomyopathy, connective tissue disorder, hyperlipidemia, ion channelopathy, or congenital heart disease. "Potentially relevant variants" were detected in 30/96 (31%) with primary myocardial fibrosis, mostly in genes related to dilated cardiomyopathy, hypertrophic cardiomyopathy, and ACM.
In a separate study, Shanks, Tester, and colleagues 5 investigated 25 deaths in people between the ages of 1 and 40 years in whom an autopsy was negative or equivocal for the exact cause of death. Application of whole exome molecular autopsy to this cohort identified 27 ultrarare variants in 99 candidate genes; ultrarare was defined as a minor allele frequency <0.00005, and variants were restricted to nonsynonymous nucleotide substitutions in coding DNA or the immediate exon/intron boundary. Using rigorous filtering and subsequent correlation with the phenotypic findings on autopsy, this group of variants was reduced to 10 that were considered pathogenic or likely pathogenic, only 6 of which matched the phenotype and were therefore "clinically actionable." Only these 6 were reported to family members seeking answers regarding the cause of death, presumably with further use in the family to risk stratify surviving family members and hopefully to reduce their likelihood of SCD.
Use of autopsies has declined worldwide over the past half-century. Rates of forensic autopsies are relatively stable, but there has been a marked decline in clinical autopsies. One study in the Netherlands reported that the clinical autopsy rate was 31.4% in 1977, with linear rate of reduction to 7.7% in 2011. 7 Despite the scientific, educational, and public health benefits of clinical autopsies, they are performed for <10% of all deaths in the USA. 8 Even though there is a class I recommendation for DNA extraction, retention, and analysis in this context, DNA is not routinely available for victims of SUDS. 9 Although DNA can be extracted from formalin-fixed paraffin-embedded tissue and used for nextgeneration sequencing, fresh blood or frozen tissue is preferable. 4 With lower costs for higher throughput DNA analysis, the expenses related to this type of clinical testing are less prohibitive now, as compared with a few years ago. Typically, medical insurance will cover clinical genetic testing at some level for outpatients, but medical insurance is usually not relevant for postmortem DNA analysis. Outside of research studies, the options for payment are for families to accept the fees, or for medical examiners and related government funding agencies to consider it an inherent part of the autopsy, just as routine histology or drug testing is utilized. Family members may not be able to make such a decision at the time of the autopsy, and another option is available. DNA banking can be a low-cost and tremendously valuable addition to an autopsy. 10 With banked DNA available for future testing, phenotypic evaluations within the family may identify a robust target for the initial genetic testing, with lower costs applied to the postmortem DNA that is restricted to targeted evaluation of suspicious variants that were found in living affected individuals. Additionally, if genetic testing is negative for a deceased individual, banked DNA can facilitate future genetic testing, as research continues to identify more options.
Variant filtering was approached differently in these studies. The Finnish investigators followed a more standard minor allele frequency <0.01, whereas the Mayo-based group used a much more stringent cutoff (minor allele frequency <0.00005). However, both then used the standards and guidelines for variant interpretation that were developed by the American College of Medical Genetics and Genomics (ACMG) with the Association for Molecular Pathology. 11 These rigorous rules apply 28 criteria addressing population data, computational analysis, functional data, and cosegregation data (or the occurrence of de novo nucleotide substitutions) to provide each rare variant a weight (stand-alone, very strong, strong, moderate, or supporting) and category (pathogenic or benign). All of this evidence is taken into account for the final classification on a scale: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or benign. Additionally, the Mayo-based group added an additional requirement for a match between the variant gene and the phenotype identified on autopsy before designating variants as "clinically actionable" and reporting them to family members. These 2 additional stringencies (minor allele frequency <0.00005 and phenotypic match) could be considered excessive, although they conclude with an important point: "The goal of these investigative studies is to provide closure to families surrounding the loss of their loved one, but perhaps the only thing worse than no answer, is to give a false answer prematurely." 5 A few genes with suspicious variants were identified in both cohorts. One should not be surprised to see RYR2 variants, which fit well with the phenotypes studied by both groups. However, many other correlations occurred in genes related to overtly structural forms of cardiomyopathy. Both studies identified TTN truncation mutations that occurred in the A-band in people with autopsy-negative or equivocal findings with unexpected sudden death. It's appropriate to ascribe pathological significance to these variants, based on overwhelming evidence of their role in contributing to dilated cardiomyopathy. 12 However, mutations in this gene are not known to be particularly proarrhythmic, and one could reasonably designate these as contributory but not solely responsible for SCD. Indeed, up to 3% of controls have TTN truncation mutations 12 ; we can only guess how many of these controls have some level of primary myocardial fibrosis. Both groups found suspicious variants in desmosomal genes (DSP, PKP2, DSG2, JUP), suggesting that these individuals died in the prodromal phase of ACM. In 1 study of ACM in the USA, nearly one-third of probands presented with fatal arrhythmia, although many of them had prior syn-cope. 13 Another study comparing ACM probands who presented with SCD or arrest with those who were diagnosed before any cardiac arrest found that SCD or arrest was associated with male sex and younger age, with a more accelerated course. 14 Other studies have linked abnormalities in the desmosome to dysfunction of the sodium channel complex, providing a potential explanation for prominent arrhythmia before the development of significant structural heart disease. 15 A similar phase of prodromal hypertrophic cardiomyopathy is suggested by the concordant findings of MYH7 and LAMP2 mutations in both studies.
As the 18th anniversary of the announcement of completion of the Human Genome project approaches, some have criticized the lack of immediate benefits in healthcare. Fortunately, studies like these published in the current issue of Circulation provide a clear step forward in understanding the genetic contributions to SUDS. Both highlight the role of whole exome molecular autopsy, demonstrating that a combination of thorough molecular and histopathologic investigation applied to victims of sudden death carries great potential to clarify the cause of death. Hopefully this will reinvigorate enthusiasm for autopsies, or at least it may encourage Medical Examiners to help the families of SUDS victims to bank and retain DNA for future analysis. 
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